Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2025-04-17 Share Issue/Capital Cha…
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing a reverse share split (share consolidation) at a ratio of 15-to-1, detailing record date, new CUSIP/ISIN, shareholder instructions, and regulatory approvals. This is a capital structure change notice (share consolidation), which falls squarely under Share Issue/Capital Change (code: SHA).
2025-04-17 English
Material change report - English.pdf
Regulatory Filings Classification · 85% confidence The document is a Canadian Form 51-102F3 “Material Change Report” filed on SEDAR describing a material change (grant of RSUs and SAB appointment). It is not a full annual or interim report, not an earnings release, not a proxy or remuneration statement, nor a share repurchase or dividend notice. It is a regulatory disclosure that does not neatly fit any other specific category, so it defaults to RNS (Regulatory Filings).
2025-04-02 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a corporate press release detailing two main announcements: the appointment of a Scientific Advisory Board chair and, more importantly from a regulatory classification standpoint, the settlement of C$70,000 of debt through the issuance of 400,000 common shares. This share issuance for debt settlement represents a change in the company's capital structure and qualifies as a financing activity update. It is not an earnings release, annual report, or AGM material, nor solely a board/director change since the SAB chair is not part of the company’s board of directors or senior management. Therefore, the best fit category is Capital/Financing Update (CAP).
2025-03-10 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, where the CFO certifies the review and fair presentation of the interim financial report and MD&A. It is not the interim report itself, nor an announcement of its publication, but a mandatory regulatory certificate filed alongside interim filings. No specific category exists for such certificates, so it defaults to the general Regulatory Filings category (RNS).
2025-02-28 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 60% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate, which is a regulatory certification by the CEO regarding the interim filings under Canadian NI 52-109. It does not contain any financial statements or MD&A itself (so it is not a full interim report) nor does it announce publication of another report. This is a regulatory compliance filing and does not fit any other specific category, therefore it falls into the “Regulatory Filings” fallback category (RNS).
2025-02-28 English
Interim MD&A - English.pdf
Management Reports Classification · 94% confidence The document is titled “Management Discussion & Analysis (MD&A) for the nine months ended December 31, 2024” and contains detailed management commentary on operations, financial performance, business development, risks, and forward-looking information. This corresponds exactly to the definition of a Management Report (MD&A). It is not just an announcement or a short notice but the full MD&A itself, so the correct classification is MDA.
2025-02-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.